Clinical Trial Detail

NCT ID NCT03482102
Title Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

biliary tract cancer

hepatocellular carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult senior

No variant requirements are available.